AVDL News and Press, Avadel Pharmaceuticals plc From 05/18/23

2023-05-18 18:38:14 ET Gainers: Farfetch Limited ( FTCH ) +18% . Ouster ( OUST ) +9%. Guardforce AI ( GFAI ) +4% . GSI Technology ( GSIT ) +4%. Losers: CaliberCos ( CWD ) -9%. Flowers Foods ( FLO ) -5%. DXC Te...

2023-05-17 02:56:26 ET Summary Key update: as we predicted, FDA approval for LUMRYZ, a unique once-at-bedtime narcolepsy treatment. Orphan Drug Exclusivity is granted until May 1, 2030, offering attractive patent protection. Launch expected in June 2023, with a fast sales ramp ant...

2023-05-05 15:44:00 ET Shares of Avadel Pharmaceuticals (NASDAQ: AVDL) were up as much as 45.5% for the week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare stock closed at $10.48 a share last week then climbed t...

2023-05-04 17:19:47 ET Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q1 GAAP EPS of -$0.48 misses by $0.10 . Cash, cash equivalents and marketable securities were $100.9 million as of March 31, 2023. The For further details see: Avadel Pharmaceutical...

-- Received FDA approval for LUMRYZ™ (sodium oxybate), the first and only once-at-bedtime oxybate for treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy – -- FDA awarded LUMRYZ Orphan Drug Exclusivity through May 1, 2030 -- -- LUMR...

2023-05-03 14:00:06 ET Summary Avadel Pharmaceuticals has received full FDA approval for Lumryz, an extended-release formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The drug's once-nightly dosing regimen give...

- Granted Orphan Drug Exclusivity through May 1, 2030 - -Advanced commercial preparations on track; LUMRYZ product availability expected in early June - - Final approval supported by robust efficacy and safety data from pivotal Phase 3 REST-ON clinical trial - - Management to host con...

2023-04-19 08:20:09 ET Summary We maintain a Buy rating for Avadel Pharmaceuticals. We expect FDA approval of Lumryz in May and a potential launch in June. Recent financing initiatives provide AVDL with a robust cash runway and an established sales force to support Lumryz's la...

DUBLIN, Ireland, April 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Con...

2023-03-31 21:25:09 ET Avadel Pharmaceuticals plc (AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Austin Murtagh – Stern Investor Relations Greg Divis – Chief Executive Officer Jennifer Gudeman – Senior ...